This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Cara Therapeutics, Inc.
Q32020
11/9/2020
Zach Satchar
Representative for David Amselin (Piper Sandler)
any initial thoughts on a size of a Durham Salesforce that you might plan to be building out? And what kind of spend, particularly direct-to-consumer activities you envision? We're just trying to get a better sense of the cost structure longer term. Thank you.
Dr. Derek Chalmers
President and CEO
Yeah. Hi, Zach. Thank you. You know, I think the latter question, we're a little too far away in terms of projecting what we're going to be spending on a commercial force there. We're just concentrating on getting that program into Phase 3 next year. Your question on Cresuva injection was related to pricing or possible pricing? I missed that.
Unidentified
Unspecified speaker (likely a follow‐up comment)
Yep. Yeah, there again.
You're reading a preview of the CARA Q3 2020 earnings call.
Free account.
Disclaimer